- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- Amondys 45, Exondys 51, Vyondys 53
- Drug
- Lead sponsor
- Kevin Flanigan
- Other
- Eligibility
- 6 Months and older · Male only
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1609–1632
of 10,850
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Pompe Disease Infantile-Onset, Glycogen Storage Disease Type II
- Interventions
- Myozyme
- Biological
- Lead sponsor
- Genzyme, a Sanofi Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2006
- U.S. locations
- 5
- States / cities
- Oakland, California • Orange, California • Omaha, Nebraska + 2 more
- Conditions
- Ductus Arteriosus, Patent
- Interventions
- Percutaneous Patent Ductus Arteriosus Closure (PPC), Responsive Management Intervention, Echocardiogram, cardiac
- Device · Combination Product · Diagnostic Test
- Lead sponsor
- Nationwide Children's Hospital
- Other
- Eligibility
- 7 Days to 32 Days
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 24
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 19 more
- Conditions
- Congenital Heart Disease, Tetrology of Fallot, RVOT Anomaly, Pulmonary Regurgitation
- Interventions
- Harmony TPV System
- Device
- Lead sponsor
- Medtronic Heart Valves
- Industry
- Eligibility
- Not listed
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2031
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Palo Alto, California • New Haven, Connecticut + 6 more
- Conditions
- Hypophosphatasia (HPP)
- Interventions
- asfotase alfa
- Biological
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 5 Years to 12 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Spinal Muscular Atrophy, Spinal Muscular Atrophy Type II, Spinal Muscular Atrophy Type 3
- Interventions
- Observational study to examine safety, tolerability, and effectiveness of SPINRAZA® prescribed as part of standard of care, One time survey
- Drug · Other
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 148 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 10
- States / cities
- Phoenix, Arizona • Washington D.C., District of Columbia • Baltimore, Maryland + 7 more
- Conditions
- Cystic Fibrosis
- Interventions
- Not listed
- Lead sponsor
- Nicole Hamblett
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 490 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 56
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Little Rock, Arkansas + 47 more
- Conditions
- Skin Laxity
- Interventions
- L.M.X.4.® cream, A placebo cream, Ulthera System Treatment
- Drug · Other · Device
- Lead sponsor
- Ulthera, Inc
- Industry
- Eligibility
- 30 Years to 65 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- Congenital Heart Disease
- Interventions
- Not listed
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- Up to 12 Weeks
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2016
- U.S. locations
- 2
- States / cities
- Madison, Wisconsin • Milwaukee, Wisconsin
- Conditions
- Fanconi Anemia
- Interventions
- JSP191, CliniMACS Prodigy System, Depleted Stem Cell Transplant, Rabbit Anti-Thymoglobulin (rATG), Cyclophosphamide, Fludarabine, Rituximab
- Drug · Device · Biological
- Lead sponsor
- Porteus, Matthew, MD
- Other
- Eligibility
- 2 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Cleidocranial Dysostosis
- Interventions
- observational
- Other
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- Not listed
- Enrollment
- 300 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2028
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Fragile X Syndrome
- Interventions
- Placebo, RO4917523 0.5 mg, RO4917523 1.5 mg
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 14 Years to 50 Years
- Enrollment
- 185 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 20
- States / cities
- Phoenix, Arizona • Long Beach, California • Sacramento, California + 17 more
- Conditions
- Autosomal Dominant Polycystic Kidney Disease
- Interventions
- Not listed
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2028
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Hemophilia B
- Interventions
- AAV5-hFIXco-Padua
- Genetic
- Lead sponsor
- CSL Behring
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2035
- U.S. locations
- 15
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 11 more
- Conditions
- Cystic Fibrosis
- Interventions
- Standard Airway Clearance device, Portable Internal Airway Percussion device
- Device
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 6 Years to 21 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Familial Mediterranean Fever
- Interventions
- colchicine sprinkle capsules
- Drug
- Lead sponsor
- Mutual Pharmaceutical Company, Inc.
- Industry
- Eligibility
- 2 Years to 65 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Atopic Dermatitis
- Interventions
- Crisaborole, Scratch sensor
- Drug · Device
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 2 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Central Line Complication, Neonatal Disease
- Interventions
- Cyanoacrylate glue, Standard transparent film dressing
- Device
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 1 Day to 6 Months
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Velopharyngeal Insufficiency, Head and Neck Cancer, Survivorship, Dysphagia, Speech Disorder
- Interventions
- Pharyngeal Wall Augmentation Injection
- Procedure
- Lead sponsor
- Vanessa Torrecillas
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- Atopic Dermatitis
- Interventions
- Nemolizumab, CYP 450 Substrates
- Drug
- Lead sponsor
- Galderma R&D
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 5
- States / cities
- North Hollywood, California • Hallandale, Florida • Miami, Florida + 2 more
- Conditions
- Von Willebrand Disease (VWD), Von Willebrand Disease (VWD), Type 1, Von Willebrand Disease (VWD), Type 2, Von Willebrand Disease (VWD), Type 3
- Interventions
- HMB-002 (Part A), HMB-002 (Part B), HMB-002 with Concomitant Factor Concentrate (Part C) (Not Applicable in US)
- Drug
- Lead sponsor
- Hemab ApS
- Industry
- Eligibility
- 16 Years to 69 Years
- Enrollment
- 108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 13
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 10 more
- Conditions
- COPD, Asthma, Cystic Fibrosis, Emphysema, Small Airways Diseases
- Interventions
- perfluorinated gas/oxygen mixture
- Drug
- Lead sponsor
- Hal C Charles
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Sickle Cell Disease, Cognitive Impairment, Adolescent Behavior, Self Efficacy, Health-Related Behavior, Coping Skills
- Interventions
- CREADY (Cognitive-Remediation of Executive and Adaptive Deficits in Youth)
- Behavioral
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 10 Years to 18 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Sickle Cell Disease
- Interventions
- Lexiscan
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 10 Years to 70 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 7
- States / cities
- Washington D.C., District of Columbia • Baltimore, Maryland • Boston, Massachusetts + 2 more